Endotoxin-mediated inflammatory pathway

The **endotoxin-mediated inflammatory pathway** refers to the complex biological cascade triggered by endotoxins—primarily lipopolysaccharides (LPS) from Gram-negative bacteria—when they interact with host immune cells. This interaction is primarily mediated through pattern recognition receptors such as Toll-like receptor 4 (TLR4), often in association with MD2. Upon activation by LPS, TLR4 initiates intracellular signaling that leads to robust secretion of pro-inflammatory cytokines and chemokines including TNFα, IL‑6, and others. This response is essential for pathogen clearance but can also result in systemic inflammation seen in conditions like sepsis[3]. Chronic or excessive activation contributes to vascular dysfunction and diseases such as atherosclerosis[2]. The phenomenon known as endotoxin tolerance describes how repeated exposure leads immune cells toward an anti-inflammatory phenotype with reduced responsiveness—a state implicated in immunosuppression during late-stage sepsis ("compensatory anti-inflammatory response syndrome," CARS)[1]. **Note:** This entry does *not* represent a single molecular therapeutic target such as a receptor or enzyme; rather it describes an entire biological process involving multiple molecules. Therefore: *is_incorrect = true*: The term "Endotoxin-mediated inflammatory pathway" is too broad for use as a canonical drug target name under standard conventions—it refers to an interconnected set of pathways rather than one discrete protein or gene product suitable for direct pharmacological targeting. For structured data purposes, individual components should be specified instead—for example “Toll-like receptor 4” (TLR4), “Caspase 11”, etc.[3]

Other names

Endotoxin signaling pathwayLPS-induced inflammatory responseLipopolysaccharide-mediated inflammation